An Evening With Experts: Selecting and Sequencing Therapy in HR+/HER2- Metastatic Breast Cancer

Friday, May 31 - Attend this dynamic, CME-certified symposium at ASCO 2019 in Chicago to get up to date on how experts are managing patients with HR+/HER2- metastatic breast cancer! Interact with the experts as they discuss best practices and emerging clinical data in an engaging, case-based format.

Sign up now! Registration is complimentary.

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

Agenda

6:30 PM - 7:00 PM: Dinner and Registration

7:00 PM - 7:10 PM: Welcome and Introduction
Joyce O’Shaughnessy, MD

7:10 PM - 7:40 PM: CDK4/6 Inhibitors in the Management of HR+/HER2- MBC
Joyce O’Shaughnessy, MD

7:40 PM - 8:10 PM: Targeting the PI3K Pathway Blockade in HR+/HER2- MBC
Sara Hurvitz, MD, FACP

8:10 PM - 8:40 PM: Promising Strategies on the Horizon for HR+/HER2- MBC
Adam M. Brufsky, MD, PhD

8:40 PM - 9:00 PM: Panel Discussion and Audience Q&A Session

Events

Date / Time
Event Details

Faculty

Program Director
Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director,
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Faculty
Adam M. Brufsky, MD, PhD

Professor of Medicine
Hematology/Oncology
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania

Faculty
Sara Hurvitz, MD, FACP

Associate Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of oncology specialists and other clinicians caring for their patients with MBC receiving CDK4/6 inhibitors, mTOR inhibitors, PI3K inhibitors, and promising investigational agents.

Target Audience
This program is intended for oncologists and other allied healthcare professionals caring for patients with metastatic breast cancer receiving targeted therapy.

Learning Objectives

  • Evaluate current guidelines and current/emerging clinical trial data on everolimus, palbociclib, ribociclib, and abemaciclib (in addition to others under clinical investigation) to aid in the refinement of current treatment algorithms for patients with de novo or recurrent HR-positive/HER2-negative MBC
  • Describe current therapeutic strategies and ongoing clinical trials of targeted therapy–based combinations for both early-stage and HR-positive, HER2-negative MBC
  • Identify ongoing trials investigating novel treatment options after disease progression on endocrine and/or CDK4/6 inhibitor–based therapy to aid in clinical trial participation

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.